Skip to main content

Advertisement

SpringerLink
Log in

Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing

  • REVIEW
  • Published:
Current Obesity Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To review the current medical therapies available for treatment of obesity in children and adolescents less than 18 years old in the United States and outline the approach to their use.

Recent Findings

Obesity is a chronic disease with increasing prevalence in children and adolescents in the United States. Over the past few years, more FDA-approved medical treatments for obesity, such as GLP-1 receptor agonists, have emerged for patients less than 18 years old. Furthermore, there are medications with weight loss effects that can be used off-label for obesity in pediatric patients. However, access to many of these medications is limited due to age restrictions, insurance coverage, and cost.

Summary

Medical options are improving to provide treatment for obesity in pediatric populations. FDA and off-label medications should be considered when appropriate to treat children and adolescents with obesity. However, further studies are needed to evaluate the efficacy and long-term safety of FDA-approved and off-label medications for obesity treatment in pediatric patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

No datasets were generated or analysed during the current study.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2): e2022060640.

    Article  PubMed  Google Scholar 

  2. Zhao G, Zhang Q, Wu F, Yin S, Xie Y, Liu H. Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2022;15(9):1119–25.

    Article  CAS  PubMed  Google Scholar 

  3. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs. 1999;58(4):743–60.

    Article  CAS  PubMed  Google Scholar 

  4. Orlistat [package insert]. Nutley (NJ): Roche laboratories, Inc; 1999.

  5. Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr. 2004;163(12):738–41.

    Article  PubMed  Google Scholar 

  6. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873.

    Article  CAS  PubMed  Google Scholar 

  7. Maahs D, de Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12(1):18–28.

    Article  PubMed  Google Scholar 

  8. Jackson IMD, Whyte WG. Chlorphentermine S.A. in the treatment of obesity and the effect of weight loss on steroid excretion. BMJ. 1965;2(5459):453–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, Fox CK. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes. 2017;41(1):90–3.

    Article  CAS  Google Scholar 

  10. Hsia DS, Gosselin NH, Williams J, Farhat N, Marier JF, Shih W, et al. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity. Diabetes Obes Metab. 2020;22(4):480–91.

    Article  CAS  PubMed  Google Scholar 

  11. •• Kelly AS, Bensignor MO, Hsia DS, Shoemaker AH, Shih W, Peterson C, Varghese ST. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1(6):10. https://doi.org/10.1056/evidoa2200014. Phentermine/topiramate has not previously been examined for efficacy and safety in a major randomized controlled trial in adolescents. With GLP-1 receptor agonist shortages, prescribers’ abilities and comfort levels to prescribe other AOMs is vital.

  12. Farr OM, Tsoukas MA, Triantafyllou G, Dincer F, Filippaios A, Ko BJ, et al. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study. Metabolism. 2016;65(7):945–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Schlögl H, Kabisch S, Horstmann A, Lohmann G, Müller K, Lepsien J, et al. Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care. 2013;36(7):1933–40.

    Article  PubMed  PubMed Central  Google Scholar 

  15. • Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–28.  This trial demonstrates the efficacy of using a daily GLP-1 receptor agonist.

    Article  CAS  PubMed  Google Scholar 

  16. • Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245–57. This trial was important in demonstrating efficacy of a weekly GLP-1 receptor agonist in adolescents to then lead to FDA approval for adolescent use.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kühnen P, Clément K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240–6.

    Article  PubMed  Google Scholar 

  18. Kühnen P, Clément K. Long-term MC4R agonist treatment in POMC-deficient patients. N Engl J Med. 2022;387(9):852–4.

    Article  PubMed  Google Scholar 

  19. Clément K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolters B, Poitou C, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551–5.

    Article  PubMed  Google Scholar 

  20. Clément K, Van Den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–70.

    Article  PubMed  Google Scholar 

  21. Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Okuyaz CMD, Kursel OMD, Komur MMD, Tamer LMD. Evaluation of appetite-stimulating hormones in prepubertal children with epilepsy during topiramate treatment. Pediatr Neurol. 2012;47(6):423–6.

    Article  PubMed  Google Scholar 

  23. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 1969. 2007;61(9):1039–48.

    CAS  Google Scholar 

  24. Zheng H, Patterson C, Berthoud HR. Behavioral analysis of anorexia produced by hindbrain injections of AMPA receptor antagonist NBQX in rats. Am J Physiol-Regul Integr Comp Physiol. 2002;282(1):R147–55.

    Article  CAS  PubMed  Google Scholar 

  25. Berman C, Naguib M, Hegedus E, Vidmar AP. Topiramate for Weight Management in Children With Severe Obesity. Child Obes. 2023;19(4):219–25. https://doi.org/10.1089/chi.2022.0062.

    Article  PubMed  Google Scholar 

  26. Fox CK, Marlatt KL, Rudser KD, Kelly AS. Topiramate for weight reduction in adolescents with severe obesity. Clin Pediatr (Phila). 2015;54(1):19–24.

    Article  PubMed  Google Scholar 

  27. Fox CK, Kaizer AM, Rudser KD, Nathan BM, Gross AC, Sunni M, et al. Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial. Obesity. 2016;24(12):2553–61.

    Article  CAS  PubMed  Google Scholar 

  28. Khazaal YMD, Chatton AMA, Rusca MBA, Preisig MMD, Zullino DMD. Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review. Gen Hosp Psychiatry. 2007;29(5):446–9.

    Article  PubMed  Google Scholar 

  29. Wang C, Shi W, Xu J, Huang C, Zhu J. Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial. Ann Gen Psychiatry. 2020;19:1–10.

    Article  CAS  Google Scholar 

  30. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011;152(12):4610–9.

    Article  CAS  PubMed  Google Scholar 

  32. DeFronzo RA, Buse JB, Kim T, Burns C, Skare S, Baron A, et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia. 2016;59(8):1645–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ford JL, Gerhart JG, Edginton AN, Yanovski JA, Hon YY, Gonzalez D. Physiologically based pharmacokinetic modeling of metformin in children and adolescents with obesity. J Clin Pharmacol. 2022;62(8):960–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014;168(2):178–84.

    Article  PubMed  Google Scholar 

  35. Carreras-Badosa G, Gómez-Vilarrubla A, Mas-Parés B, Martínez-Calcerrada JM, Xargay-Torrent S, Prats-Puig A, et al. A 24-month metformin treatment study of children with obesity: changes in circulating GDF-15 and associations with changes in body weight and visceral fat. Pediatr Obes. 2022;17(2): e12845.

    Article  PubMed  Google Scholar 

  36. Concepcion JQ, Tucker LY, Huang K. Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system. Obesity. 2021;29(9):1526–37.

    Article  CAS  PubMed  Google Scholar 

  37. Asanka de Silva V, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.

    Article  Google Scholar 

  38. Ermer JC, Pennick M, Frick G. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36(5):341–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Guerdjikova AI, Blom TJ, Mori N, Matthews A, Cummings T, Casuto LL, et al. Lisdexamfetamine in pediatric binge eating disorder: a retrospective chart review. Clin Neuropharmacol. 2019;42(6):214–6.

    Article  CAS  PubMed  Google Scholar 

  40. Banaschewski T, Johnson M, Nagy P, Otero IH, Soutullo CA, Yan B, et al. Growth and puberty in a 2-year open-label study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2018;32(5):455–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Greig SL, Keating GM. Naltrexone ER/bupropion ER: a review in obesity management. Drugs. 2015;75(11):1269–80.

    Article  CAS  PubMed  Google Scholar 

  42. Billes SK, Greenway FL. Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother. 2011;12(11):1813–26.

    Article  CAS  PubMed  Google Scholar 

  43. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006;443(7109):289–95.

    Article  CAS  PubMed  Google Scholar 

  44. White MA, Grilo CM. Bupropion for overweight women with binge eating disorder: randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2013;74(4):400–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + bupropion combination for the treatment of binge-eating disorder with obesity: a randomized, controlled pilot study. Clin Ther. 2021;43(1):112-122.e1.

    Article  CAS  PubMed  Google Scholar 

  46. Prof GFL, Fujioka KMD, Prof PRA, Prof MS, Guttadauria MMD, PhD EJ, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Br Ed. 2010;376(9741):595–605.

    Article  Google Scholar 

  47. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O’Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19(1):110–20.

    Article  CAS  PubMed  Google Scholar 

  48. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained- release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obes Silver Spring Md. 2013;21(5):935–43.

    Article  CAS  Google Scholar 

  50. Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022;387(5):433–43.

    Article  CAS  PubMed  Google Scholar 

  51. Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D’Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Available from: https://insight.jci.org/articles/view/140532.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.

    Article  CAS  PubMed  Google Scholar 

  53. Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–55.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Heinberg LJ, Bond DS, Carroll I, Crosby R, Fodor A, Fouladi F, et al. Identifying mechanisms that predict weight trajectory after bariatric surgery: rationale and design of the biobehavioral trial. Surg Obes Relat Dis. 2020;16(11):1816–26.

    Article  PubMed  PubMed Central  Google Scholar 

  55. El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps—a scoping review. Obes Surg. 2021;31(4):1755–66.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Helmrath MA, Brandt ML, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374(2):113–23.

    Article  CAS  PubMed  Google Scholar 

  57. Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Brandt ML, Xanthakos SA, et al. Five-year outcomes of gastric bypass in adolescents as compared with adults. N Engl J Med. 2019;380(22):2136–45.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Istfan NW, Anderson WA, Hess DT, Yu L, Carmine B, Apovian CM. The mitigating effect of phentermine and topiramate on weight regain after Roux-en-Y gastric bypass surgery. Obesity. 2020;28(6):1023–30.

    Article  CAS  PubMed  Google Scholar 

  59. Murvelashvili N, Xie L, Schellinger JN, Mathew MS, Marroquin EM, Lingvay I, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity. 2023;31(5):1280–9.

    Article  CAS  PubMed  Google Scholar 

  60. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT05726227, A research study on how well semaglutide helps children and teenagers with excess body weight lose weight (STEP Young). 2023. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05726227.

  61. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514–26. Available from: https://doi.org/10.1056/NEJMoa2301972.

    Article  CAS  PubMed  Google Scholar 

  62. Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1): e2033457.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877–88.

    Article  CAS  PubMed  Google Scholar 

  64. Lawson EA, Olszewski PK, Weller A, Blevins JE. The role of oxytocin in regulation of appetitive behavior, body weight and glucose homeostasis. J Neuroendocrinol. 2020;32(4): e12805.

    Article  CAS  PubMed  Google Scholar 

  65. Hong SM, Ko JK, Moon JJ, Kim YR. Oxytocin: a potential therapeutic for obesity. J Obes Metab Syndr. 2021;30(2):115–23.

    Article  PubMed  PubMed Central  Google Scholar 

  66. ClinicalTrials.gov [Internet]. Bethesda (MD): National library of medicine (US). 2000 Feb 29. Identifier NCT04551482, Oxytocin for weight loss in adolescents. 2020. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04551482.

  67. Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011;171(7):703–4.

    Article  PubMed  Google Scholar 

  68. Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, et al. Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity. Obesity. 2019;27(2):190–204.

    Article  PubMed  Google Scholar 

  69. Phentermine [package insert]. Sellersville (PA): Teva Pharmaceuticals USA; 1959.

  70. Qsymia [package insert]. Winchester (KY): Catalent Pharma Solutions, LLC; 2012.

  71. Saxenda [package insert]. Plainsboro (NJ): Novo Nordisk Inc; 2014.

  72. Wegovy [package insert]. Plainsboro (NJ): Novo Nordisk Inc; 2022.

  73. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, De Boer AS, Drucker DJ, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–86.

    Article  PubMed  Google Scholar 

  74. Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384–90.

    Article  CAS  PubMed  Google Scholar 

  75. Imcivree [package insert]. Boston (MA): Rhythm pharmaceuticals, Inc; 2020.

  76. Glucophage [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2000.

  77. Pastor-Villaescusa B, Cañete MD, Caballero-Villarraso J, Hoyos R, Latorre M, Vázquez-Cobela R, et al. Metformin for obesity in prepubertal and pubertal children: a randomized controlled trial. Pediatrics. 2017;140(1): e20164285.

    Article  PubMed  Google Scholar 

  78. Masarwa R, Brunetti VC, Aloe S, Henderson M, Platt RW, Filion KB. Efficacy and safety of metformin for obesity: a systematic review. Pediatrics. 2021;147(3): e20201610.

    Article  PubMed  Google Scholar 

  79. Topiramate [package insert]. Titusville (NJ): Janssen Pharmaceuticals, Inc; 1996.

  80. Vyvanse [package insert]. Lexington (MA): Shire US Inc; 2007.

  81. Contrave [package insert]. Deerfield (IL): Takeda Pharmaceuticals America, Inc; 2014.

Download references

Funding

J.M. was supported by a T32 training grant for Endocrinology (T32DK007028-47S1).

Author information

Author notes

  1. Yoon Ji Ahn and Jacqueline Maya contributed equally.

Authors and Affiliations

  1. Division of Endocrinology-Metabolism Unit, Department of Internal Medicine, Massachusetts General Hospital, MGH Weight Center, Boston, MA, USA

    Yoon Ji Ahn

  2. Harvard Medical School, Boston, MA, USA

    Yoon Ji Ahn, Jacqueline Maya & Vibha Singhal

  3. Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA

    Jacqueline Maya & Vibha Singhal

Authors
  1. Yoon Ji Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacqueline Maya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vibha Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Yoon Ji Ahn and Jacqueline Maya were co-first authors for the paper and contributed equally to acquiring data and reviewing articles for the manuscript, writing of the manuscript, tables, and figures and contributed to reviewing and editing of the manuscript. Vibha Singhal acted as the senior author and reviewed and revised the manuscript, tables, and figures and approved the manuscript for publication.

Corresponding author

Correspondence to Vibha Singhal.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent 

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahn, Y.J., Maya, J. & Singhal, V. Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing. Curr Obes Rep (2024). https://doi.org/10.1007/s13679-024-00566-z

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13679-024-00566-z

Keywords

Search

Navigation